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Surveillance  for intussusception  is a post  marketing  requirement  for rotavirus  vaccines  following  obser-
vation  of  a small  increased  risk  of  intussusception  after  rotavirus  vaccination  in  some  global  settings.
This  study  presents  the  clinical  presentation  and  outcomes  of  children  who  presented  with  intussuscep-
tion  at  a large  tertiary  care  facility  directly  (non-surveillance)  as  retrospective  analysis  of a  period  where
rotavirus  vaccine  was  not  in routine  use,  or as part  of  active  surveillance  in  a phase  III oral  rotavirus
vaccine  trial.
Hospital  records  of children  under  2  years  of age treated  for intussusception  between  1 January  2010
and  31  August  2013  at the  Christian  Medical  College  Hospital,  Vellore,  India,  were  reviewed.  Sixty-one
cases  of  intussusception  in  children  under  two  years  of  age presented  at the  hospital.  An  additional  16
cases  of  ultrasound  diagnosed  intussusception  were  identiﬁed  through  the  active  surveillance  of  a cohort
of  1500  children  participating  in  a rotavirus  phase  III trial in  the  same  period.
In  the  nonsurveillance  group,  median  age  at presentation  was  214  days  (IQR  153–321) with  52 events
(85.3%)  occurring  in  the  ﬁrst  year  of life. Cases  were  seen  year-round  with  no  deﬁnitive  evidence  of
seasonality.  Thirty-one  (50.8%)  intussusceptions  required  surgical  reduction,  26  (42.6%)  had  pneumatic
reduction  and  2 (3.3%)  barium  enema  reduction.  Two  intussusceptions  (3.3%)  resolved  spontaneously.
There  were  no  deaths,  all  children  were  discharged  after recovery.
Active surveillance  identiﬁed  16  children  with  a median  age  at event  of  375 days  (IQR  248–574).
Nine  (56%)  children  had  small  bowel  or  transient  intussusception  that  resolved  spontaneously.  Seven
intussusceptions  were  reduced  radiologically;  none  required  surgery.In  summary,  there  were signiﬁcant  differences  between  presentation  and  outcomes  in  cases  of  intus-
susception  identiﬁed  by passive  and  active  surveillance,  likely  related  to enhanced  and  early  detection
of  intussusception  through  active  monitoring  in  the  trial.  The  WHO  recommendation  of  sentinel  hospi-
tal  based  surveillance  for post-marketing  surveillance  after  rotavirus  vaccine  introduction  is  likely  to  a
better approach  than  active  surveillance.
d  by © 2014  Publishe
. Introduction
Rotavirus diarrhea contributes to an estimated 450,000 annual
hildhood deaths globally and is the most important cause of diar-
heal mortality in the developing world [1]. Effective vaccines
o prevent rotavirus diarrhea are licensed and available in sev-
ral countries and offer a potent public health intervention in
∗ Corresponding author at: Division of Gastrointestinal Sciences, Christian Medical
ollege, Vellore, TN 632004, India. Tel.: +91 416 228 2052.
E-mail address: gkang@cmcvellore.ac.in (G. Kang).
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.028
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC BElsevier  Ltd.  This  is an  open  access  article  under the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
high mortality developing country settings [2]. Since 1999, when
a tetravalent rhesus reassortant rotavirus vaccine (RotaShield,
Wyeth Laboratories, Marietta, Pennsylvania) was  linked to a
1 in 10,000 excess risk of intussusception following rotavirus
immunization [3,4], concerns regarding intussusception have been
associated with rotavirus vaccination. Currently licensed vaccines
from Glaxo Smith Kline and Merck were evaluated in large safety
studies that did not demonstrate increased risk of similar magni-
tude [5,6]. However postlicensure studies with both these vaccines,
have identiﬁed a safety signal with 1–5 excess cases of intussus-
ceptions in 100,000 immunized infants in different parts of the
world [7–11]. While the risk beneﬁt ratio of these vaccines remains
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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verwhelmingly in favor of the vaccine [9,12], these concerns are
ikely to be key considerations in decision-making around intro-
uction in a National Immunization Program (NIP).
When a new vaccine, especially one with a well-publicised,
lbeit rare, adverse event is introduced into a NIP, height-
ned awareness is likely to result in early reporting of events
ncluding self-limiting events which would not earlier have been
ocumented. Interpreting post-introduction surveillance data of
dverse events requires careful planning and an understanding
f underlying event rates [13]. Intussusception, the common-
st cause of acute intestinal obstruction in infants, involves the
nvagination of a bowel segment into another, and may  occur in
ifferent segments of the small and large intestines. Large bowel
ntussusception, and the ileocecal type where the ileum invagi-
ates through the ileocecal valve into the cecum often result in
ntestinal ischemia and intestinal obstruction requiring radiolog-
cal or surgical intervention. On the other hand, transient small
owel intussusceptions (ileo-ileal) are common, generally asymp-
omatic or mildly symptomatic and usually resolve spontaneously
14].
Cases of pediatric intussusception that presented to a large ter-
iary care centre in southern India from January 2010 to August
013 were retrospectively reviewed in 2013. This facility also
erved as the primary referral facility for intussusception cases
dentiﬁed through active surveillance during a phase III rotavirus
accine trial which recruited 1500 children from April 2011 to
ovember 2011 and followed them until they reached 2 years
f age, with follow up ending in September 2013. The analysis
f safety data in the phase III trial did not reveal any statis-
ically signiﬁcant difference in the incidence of intussusception
eeting Brighton level 1 diagnostic certainty in vaccinees or
lacebo recipients [15]. We  describe the presentation, management
nd outcomes of children with intussusception who  presented
outinely at the hospital (deﬁned as non-surveillance intussus-
eption cases collected by retrospective analysis) as well as those
ho were detected through an active surveillance program as a
art of safety monitoring of the vaccine trial (deﬁned as surveil-
ance intussusception cases). This study may  inform appropriate
mplementation and interpretation of intussusception surveillance
ost-licensure of rotavirus vaccines in similar developing country
ettings.
. Materials and methods
.1. Retrospective study
A retrospective review of all children 0–2 years of age with
ntussusceptions treated between 1st January 2010 and 31st August
013 at Christian Medical College and Hospital (CMC), Vellore was
ndertaken. This hospital with 2695 beds caters to 1.9 million out-
atients and 120,000 inpatients annually, is the largest healthcare
acility in the region and is the sole provider of pediatric surgery
ervices in Vellore district, which has a population of about four
illion people.
Cases were identiﬁed in a two-step process. Possible cases
f intussusception were ﬁrst identiﬁed by an electronic search
f the radiology database and operation registers. Ultrasound
eports of all children who had an ultrasound of the abdomen
ere searched for keywords related to intussusception. All
hildren less than 2 years of age with an ultrasound diag-
osis of intussusception requiring intervention were included
n the study. The diagnosis of intussusception was then con-
rmed by reviewing the medical records, operation notes and
ther investigations and entered into a database by one of the
nvestigators.2S (2014) A99–A103
2.2. Active surveillance in a vaccine trial
Additionally, as part of safety surveillance of a phase III rotavirus
vaccine trial, 1500 infants recruited between April and November
2011 at the age of 6 weeks were randomized in a 2:1 ratio of vaccine
to placebo and were actively followed up with weekly contacts by
ﬁeld workers until they reached two  years of age. All participants
in this trial were provided mobile phones and access to a call cen-
ter around the clock for the duration of follow up. They were also
contacted weekly by ﬁeld workers to check on the health status of
the child. Any child with a history of blood in stools (any quantity
including streaking), or continuous vomiting ( > = 3 episodes in an
hour) or any abdominal distension or abdominal lump was  con-
sidered a case of suspected intussusception and was  reviewed by a
pediatrician in the study team or at the CMC  hospital. The criteria for
screening were agreed on by an expert group of pediatricians prior
to development of the clinical trial protocol and were designed to be
broad and sensitive, such that risk was  minimized by ensuring that
study investigators intensively followed up and arranged appropri-
ate management for each child suspected to have intussusception.
A screening ultrasonagram was performed by a trained sonologist
on participants who  had symptoms or signs conﬁrmed on review by
the study pediatrician. Those identiﬁed to have an intussusception,
including transient intussusception, were reviewed by a pediatric
surgeon and managed according to standard treatment algorithms
and classiﬁed according to the Brighton criteria [16] by an off-site
adjudication committee. Clinical data from hospital records of trial
participants was  abstracted by a pediatric surgeon and compared
to data maintained at the clinical trial site by a second investiga-
tor.
Data were entered in Microsoft Excel and analyzed using Stata
11 (StataCorp, 2009). The incidence rate of symptomatic intussus-
ception and those that were Brighton level 1 were calculated from
the event rate in this cohort. Incidence rates and 95% CI were cal-
culated assuming a Poisson distribution.
3. Results
3.1. Intussusceptions presenting through routine care identiﬁed
on retrospective analysis
Apart from the 16 intussusceptions identiﬁed in the vaccine
trial and described separately below, 61 children under two years
of age had a diagnosis of intussusception made at CMC  between
January 2010 and August 2013. Thirty-one (50.8%) were referred
from another hospital while 30 (49.2%) presented directly at CMC.
The median time from onset of symptoms to arrival at the hospital
was 48 h (range 6–240 h). The median age at presentation was  214
days (IQR 153–321) with 52 events (85.3%) occurring in the ﬁrst
year of life. As shown in Fig. 1, the age distribution was  unimodal
with a peak between 4 and 6 months of age. Males (42, 65.8%) were
twice as likely to present with intussusception as females in this
setting.
In all 61 intussusceptions evidence of intestinal invagination
was present on ultrasonogram. The admission notes of two chil-
dren were not traced in the records. The presenting symptoms for
59 of the 61 patients whose records were complete is presented
in Table 1. Evidence of intestinal obstruction was noted in 27 cases
(45.8%). Evidence of intestinal vascular compromise assessed by the
passage of blood in stools or red currant jelly stools was present in
55 patients (93.2%).Based on the Brighton Collaboration Intussusception Working
Group criteria [16], 59 (96.7%) children met  level 1 diagnostic cer-
tainty and 2 (3.3%) met  level 2. Surgical intervention was  required
in 31 (50.8%) children. Sixteen (51.6%) of those children who had
S. Jehangir et al. / Vaccine 3
Fig. 1. Distribution of age at presentation in children under two  years of age with
intussusception identiﬁed through retrospective survey (n = 61).
Table 1
Presenting features of intussusception in children under 2 years (n = 59) identiﬁed
through retrospective analysis at the CMC  Hospital in Vellore between 2010 and
2013 and those with active surveillance in a Phase III rotavirus vaccine trial.
Presenting feature Retrospective
analysis, N (%)
Active surveillance,
N (%)
Abdominal distension 11 (18.6) 2 (12.5)
Continuous vomiting 38 (64.4) 14 (87.5)
Bilious vomiting 18 (30.5) 0
Bleeding per
rectum/red currant
jelly stool
55 (93.2) 9 (56.3)
Abdominal pain 28 (47.5) 0
Lethargy 19 (32.2) 1 (6.3)
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4. Discussionig. 2. Seasonal distribution of intussusception in children under 2 years (n = 77).
urgery had bowel loss and 3 (9.7%) required a stoma. While in
eneral, surgery was undertaken where radiological reduction was
nsuccessful, direct surgery without radiological reduction was
erformed in 2 children who presented in shock and one with small
owel persistent intussusception and polyposis.
Nonoperative reduction was achieved pneumatically in 26
42.6%) and by barium in 2 (3.8%) children. One child arrested dur-
ng pneumatic reduction and was successfully resuscitated while
ne had an intestinal perforation. Both children had good outcomes.
ll children were well at discharge from hospital. Cases of intussus-
eption were observed year-round with relatively more cases from
ovember to April (Fig. 2).2S (2014) A99–A103 A101
3.2. Intussusception identiﬁed through active surveillance and
referral of a vaccine trial cohort
The 1500 children enrolled in the phase III vaccine trial pro-
vided 1294 child years of observation between six weeks and
the ﬁrst birthday and 1461 child years in the second year of life
after excluding those who died, were censored or had temporar-
ily moved from study settings. Five hundred and three episodes
meeting the screening criteria for suspected intussusception were
identiﬁed. Of these, 489 episodes were reviewed by a study pedi-
atrician and 444 were referred for and had an ultrasonogram.
In fourteen of 503 episodes, the parents either refused screen-
ing or were outside the study area. Of the episodes evaluated by
the study pediatrician, 45 were asymptomatic or did not meet
criteria for referral for ultrasonogram at the time of examina-
tion. The high rate of referral for ultrasound reﬂected the cautious
approach taken to apply the protocol deﬁned broad screening crite-
ria expected to minimize any possible risk in a placebo-controlled
trial. Sixteen intussusceptions were identiﬁed of which, 7 met
the Brighton Collaboration Intussusception Working Group level
1 diagnostic certainty, while 6 met  level 2 criteria and 3 transient
intussusceptions did not meet any level of Brighton criteria. For
the 16 ultrasound diagnosed intussusceptions, the median time
from onset of symptoms to follow up by the health care team
was 10.3 h (range 4 to 48 h). Nine of 16 intussusceptions identi-
ﬁed in active surveillance were ileocecal. One was  colocolic and the
other 6 were small bowel intussusceptions. All intussusceptions
requiring intervention were ileocecal. Two ileocecal intussuscep-
tions were transient. Six of the 7 Brighton level 1 intussusceptions
were reduced pneumatically under ﬂuroscopy, 1 was reduced by
barium enema and none required surgery. One child had a recur-
rence within 24 h of pneumatic reduction and required a repeat
pneumatic reduction. The remaining 9 intussusceptions were tran-
sient and resolved spontaneously. Eight of the 16 intussusceptions
(50%) occurred in the ﬁrst year of life with 4 meeting level 1, 3 level
2 and 1 not meeting Brighton criteria for any level of diagnostic
certainty.
In the phase III study, the incidence rate of ultrasound diagnosed
intussusception was 581 per 100,000 child years (95% CI 332, 943)
and of Brighton level 1 intussusception was 254 per 100,000 child
years (95% CI 102, 524) in children under active surveillance till 2
years of age. The rate of ultrasound diagnosed intussusception in
the second half of the ﬁrst year of life (738 child years of obser-
vation), which is considered the period of greatest risk, was  949
per 100,000 child years (95% CI 381, 1954) while that for intus-
susception meeting Brighton level 1 criteria was 406 per 100,000
child years (95% CI 83, 1188). The median age of intussusception
in the surveillance cohort of 375 days (IQR 248–574) was signif-
icantly higher than that of children presenting from the general
population where the median was 214 days (IQR 153–321 days)
(p = 0.001).
Cases of intussusception identiﬁed through active surveillance
were signiﬁcantly less likely to show evidence of obstruction and
ischemia (Table 2) and therefore less likely to require surgical inter-
vention as compared to those who routinely present to tertiary care
pediatric surgery facilities with intussusception. This is supported
by the fact that even among the intussusceptions that met Brighton
level 1 criteria, none of those identiﬁed through active surveillance
and 31 (50.8%) of those directly presenting to hospital required
surgery.The global average for intussusception rates is estimated at
74 per 100,000 child years [17], with the highest rates being
A102 S. Jehangir et al. / Vaccine 32S (2014) A99–A103
Table 2
Comparison of the characteristics of intussusception in children presenting routinely from the general population identiﬁed on retrospective analysis and those actively
followed up in a phase III rotavirus vaccine trial and referred in case of suspected intussusception.
Variable General population (%) (n = 59) Active surveillance (%) (n = 16) P-value (Fisher’s Exact)
Evidence of intestinal obstruction 27 (45.8) 2 (12.5) 0.020
Evidence of intestinal ischemia 55 (93.2) 9 (56.2) 0.001
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rotavirus vaccine. NEJM 2006;354(1):23–33.
[7] Shui IM, Baggs J, Patel M,  Parashar UD, Rett M,  Belongia EA, et al. Risk of intus-
susception following administration of a pentavalent rotavirus vaccine in USConservative treatment before referral 31 (52.5) 
Requiring intervention 57 (96.7) 
eported from Vietnam (287 and 302 per 100,000 in Ho Chi Minh
ity and Hanoi, respectively and Korea (328 per 100,000) [18–20].
hese rates were largely based on passive surveillance where cases
ere captured in hospitals from deﬁned populations. With inten-
ive, active surveillance, the incidence of intussusception meeting
righton level 1 diagnostic certainty in 1500 children in Vellore
254 per 100,000 children) was similar to the highest global rates,
hich while not using active surveillance also have a high rate of
ltrasound use for diagnosis of intussusception [18].
When active surveillance using broad screening criteria such as
hose employed in the rotavirus phase III trial is undertaken, many
otential cases might be identiﬁed that may  not meet the criteria
or level 1 diagnostic certainty of intussusception, as demonstrated
y the ﬁnding of 16/444 positive ultrasonograms. Even among the
ositive ultrasonograms, a large number of transient intussuscep-
ions of doubtful clinical signiﬁcance are likely to be identiﬁed
nﬂating the incidence of intussusception. Transient intussuscep-
ion, especially within segments of the small bowel in the absence
f a lead point, may  be a coincidental ﬁnding and correlating it
ith the clinical condition and presentation is central to the clin-
cal decision-making process. This is particularly relevant when a
road screening criterion such as blood in stool is used for referral
n situations where bacillary dysentery and other infectious causes
or hematochesia are relatively common. Any active intervention
ould then convert a potential transient intussusception to level 1
iagnostic certainty. Therefore, standardized clinical algorithms for
ecision on radiological or surgical intervention would be central to
entinel surveillance programs for intussusception that categorize
ntussusception based on Brighton criteria. It is important to note
hat the Brighton criteria were evolved as a tool for use in relat-
ng an adverse event to vaccination [16] and not for use in clinical
iagnosis of intussusception.
It is likely that the sensitive screening criteria and heightened
wareness of the risk of intussusception in the context of a phase
II rotavirus trial among the study physicians, increased the proba-
ility of referral for symptoms that might normally be ignored. The
elatively early referral and ultrasound screening of suspected cases
learly contributed to transient, spontaneously resolving intussus-
eptions being picked up on radiological examination.
Of the intussusceptions identiﬁed during the vaccine trial, 9 of
6 were small bowel intussusceptions, and the majority resolved
pontaneously and none required surgical intervention. A study
hich examined small bowel intussusceptions, showed that most
leal intussusceptions (84%) were transient and the only cases
here ileal intussusceptions were persistent or interventions were
equired, there was underlying pathology such as infection, stric-
ure or abscess [14].
In the retrospective analysis, the number of cases of intussus-
eption had tripled at this referral facility in Vellore since the last
eport by Bhowmik between 2001 and 2004 [21]. This may reﬂect
 number of factors including the improved diagnostic facilities,
idening catchment population and changes in health seeking
ractices. About 51% of intussusceptions presenting in the tertiary
are hospital were referred to the center after receiving preliminary
reatment elsewhere, and fewer children had an evident lead point
or intussusception in this cohort as compared to previous studies1 (6.3) 0.001
7 (43.8) 0.000
from Vellore [21,22], but those studies included older children as
well.
This study demonstrates intussusceptions identiﬁed through
active surveillance and those identiﬁed through retrospective
hospital based surveillance, differ in the presentation, severity
of illness, need for intervention and outcomes. Transient intus-
susception happens frequently in children and rarely requires
intervention [14], and most likely is without a temporal relation-
ship to vaccination. When considering intussusception as a possible
consequence of rotavirus vaccination, it is important to consider
which outcomes are important for safety monitoring. Clearly, if
transient ileal intussusceptions are a frequent self resolving event
in children, it would be difﬁcult to assign causality to such events
even when they occur in temporal relationship to vaccination.
On the other hand, intussusceptions that do not resolve spon-
taneously and require intervention, whether by reduction under
radiologic guidance or at surgery, which occur in the risk win-
dow after any dose of vaccine must be captured and provided
rapid access to appropriate medical care. The World Health Orga-
nization’s guidance for post-marketing surveillance for rotavirus
vaccines suggests a sentinel hospital approach where an estimate
of the catchment area is possible [23]. Based on the data pre-
sented here, the WHO  approach represents a feasible and pragmatic
approach to identiﬁcation of cases of intussusception, based on
which studies on vaccine safety can be designed, but careful atten-
tion to data quality will be critical [24].
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